IPP Bureau
Delhi becomes 35th state/UT to implement AB PM-JAY
By IPP Bureau - April 07, 2025
Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme
Plex Research partners With Ginkgo Bioworks on AI powered drug discovery to identify novel disease mechanisms
By IPP Bureau - April 07, 2025
Findings likely to generate hypotheses about potential new uses of drugs
Siemens acquires Dotmatics for $5.1 billion to strengthen Life Sciences portfolio
By IPP Bureau - April 07, 2025
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
Alife expands personal care portfolio with Gondhoraj & Neem soap in West Bengal
By IPP Bureau - April 07, 2025
The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience
Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
By IPP Bureau - April 07, 2025
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Fluor to provide EPCM services for pharmaceutical facility in Indiana
By IPP Bureau - April 07, 2025
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
By IPP Bureau - April 07, 2025
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Lupin acquires UK-based Renascience Pharma for £12.3 million
By IPP Bureau - April 04, 2025
The portfolio includes branded injectable cephalosporines for infectious diseases
Gland Pharma receives approval for Acetaminophen Injection
By IPP Bureau - April 04, 2025
The company expects to launch this product through its marketing partner in the near future
Sai Life Sciences sets up Peptide Research Center in India
By IPP Bureau - April 04, 2025
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
SPARC announces submission of IND Application for SBO-154 to USFDA
By IPP Bureau - April 04, 2025
The IND application supports the next phase of development of SBO-154
Roche presents novel therapeutic and diagnostic advancements in Alzheimer’s at AD/PD 2025
By IPP Bureau - April 04, 2025
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
By IPP Bureau - April 04, 2025
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
By IPP Bureau - April 04, 2025
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
